Hanmi Pharm Appoints Directors Kim Jae-kyo and Choi In-young: "Fully Committed to Enhancing Shareholder Value"

Shifting Focus to Results-Driven Research,
Delivering Tangible New Drug Achievements

Hanmi Pharmaceutical appointed former Meritz Securities Vice President Kim Jae-kyo and Hanmi Pharmaceutical R&D Center Director Choi In-young as new directors at the shareholders' meeting.

On the 26th, Hanmi Pharmaceutical held its regular shareholders' meeting at the Hanmi Tower Building in Songpa-gu, Seoul, and appointed Choi In-young as an inside director, Kim Jae-kyo as a non-executive director, and Lee Young-gu as an outside director (Lee Young-gu, representative lawyer of the law firm Dae-ryuk Aju). Other agenda items, including approval of the financial statements and consolidated financial statements and partial amendments to the articles of incorporation, were also approved as originally proposed.

Director Kim Jae-kyo has been designated as CEO of the holding company Hanmi Science and joined Hanmi Science as vice chairman earlier this month. He is a pharmaceutical expert who oversaw management planning, global strategy, technology transfer, and mergers and acquisitions (M&A) at Yuhan Corporation for 30 years. After working at Janssen (now Innovative Medicine) in 2018, he joined Meritz Securities in 2021, leading the IND division that discovers and nurtures bio ventures.

Director Choi In-young has participated in various new drug developments within the Hanmi Group for 27 years, leading several global technology transfer achievements. Currently, as the head of the R&D Center, she oversees Hanmi Pharmaceutical’s new drug development operations.

Hanmi Pharmaceutical CEO Park Jae-hyun said, "Last year was turbulent, but we deeply considered the encouragement from shareholders and started this year anew. We achieved the highest-ever sales last year, recorded industry-leading operating profits, and produced about 20 blockbuster drugs in the outpatient prescription market, maintaining the number one position in outpatient prescription performance for seven consecutive years."

He added, "We are on the verge of commercialization in the obesity treatment field based on advanced technology. Although we achieved many results last year, I feel heavy-hearted when thinking about the stock price. In 2025, we will show shareholders a completely transformed Hanmi as we start anew."

He continued, "In R&D, we will shift from research for the sake of research to research aimed at results, rewarding with tangible new drug outcomes. We will communicate with shareholders and devote all efforts to enhancing shareholder value."

He also said, "Director Kim Jae-kyo is an expert with over 30 years of experience in pharmaceutical and bio strategies such as management planning and M&A, having previously worked at Yuhan Corporation and others. This is a strategy to expand into the global market based on his deep expertise and global network, including leading technology exports. The appointment of these two individuals will determine the future direction of the company."

Regarding inside director Choi In-young, CEO Park explained, "Choi In-young has built various platforms for new drug development at Hanmi for 27 years and successfully led global technology exports. She oversees Hanmi’s new drug development. By securing growth engines and focusing on new modalities, she will lead the company by establishing another new drug pipeline."

Meanwhile, the regular shareholders' meeting of Hanmi Science, the holding company of Hanmi Pharmaceutical, is also scheduled for 10 a.m. on the same day.